Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process
Objective: The Parkinson Progression Markers Initiative (PPMI) is a multinational, longitudinal observational study that collects clinical, imaging, biologic, and genetic data from participants with or…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins
Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…Unraveling Plantar Pressure Dynamics in Parkinson’s Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors
Objective: To elucidate plantar pressure characteristics in different stages of PD patients who experienced FOG and identify predictive factors for alterations in plantar pressure parameters.…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Evaluation of neuroprotective effects of doxycycline in a primate model of PD
Objective: To evaluate the effects of doxycycline on the outcomes of 6-OHDA-induced Parkinson's disease in Sapajus apella monkeys. Background: Doxycycline (doxy) has been reported as…Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review
Objective: To evaluate the evidence regarding (1) deep brain stimulation (DBS) effectiveness in case of postoperative cognitive deterioration, (2) the impact of preoperative cognition on…AAV-mediated gene therapy for GBA-PD
Objective: Development of a gene therapy-based drug for treatment of GBA-PD, a genetic subtype of Parkinson’s disease Background: Mutations in GBA1, the gene encoding glucocerebrosidase…Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence
Objective: To develop a machine learning (ML) algorithm capable of predicting the optimal deep brain stimulation (DBS) contact based on neurophysiology. Background: DBS is an…The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease
Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…
- 1
- 2
- 3
- …
- 338
- Next Page »